Form 4: Myriad Genetics COO Acquires Shares Through Employee Stock Purchase Plan

Sentiment:

SEC Form 4 Filing


Myriad Genetics Chief Operating Officer, Samraat S. Raha, acquired 1,118 shares of common stock through the company's employee stock purchase plan.

Summary

  • Samraat S. Raha, the Chief Operating Officer of Myriad Genetics Inc., acquired 1,118 shares of common stock on November 30, 2024.
  • The shares were purchased at a price of $13.83 per share.
  • The transaction was made under the company's 2012 Amended and Restated Employee Stock Purchase Plan.
  • Following the transaction, Mr. Raha directly owns 301,972 shares of Myriad Genetics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as it reflects a routine transaction under an employee stock purchase plan, indicating confidence from the COO in the company's stock.

Positives

  • The purchase of shares by a high-ranking officer demonstrates confidence in the company's future prospects.
  • The employee stock purchase plan allows employees to invest in the company at a potentially favorable price.

Industry Context

This is a routine transaction related to employee compensation and is common in publicly traded companies. It does not indicate any specific trend in the biotech industry.

Comparison to Industry Standards

  • Employee stock purchase plans are a common practice among publicly traded companies, particularly in the technology and biotech sectors.
  • The number of shares acquired is relatively small compared to the total outstanding shares of Myriad Genetics, and is typical for an employee stock purchase plan.
  • Similar transactions are regularly reported by executives at comparable companies such as Exact Sciences (EXAS) and Illumina (ILMN).

Stakeholder Impact

  • The transaction has a minor positive impact on shareholders as it shows confidence from a key executive.
  • The employee stock purchase plan benefits employees by allowing them to acquire company stock.

Key Dates

DateDescription
11/30/2024Date of the share acquisition by Samraat S. Raha.
12/02/2024Date the Form 4 was signed.

Keywords

Myriad Genetics, Employee Stock Purchase Plan, Share Acquisition, Samraat S. Raha, Chief Operating Officer, MYGN, Insider Trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.